Zacks Investment Research upgraded shares of GW Pharmaceuticals (NASDAQ:GWPH) from a sell rating to a hold rating in a report released on Wednesday, March 21st.
According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
GWPH has been the topic of several other research reports. BidaskClub upgraded GW Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, December 22nd. Leerink Swann restated a buy rating and set a $153.00 target price on shares of GW Pharmaceuticals in a research report on Tuesday, January 23rd. Cantor Fitzgerald restated a buy rating and set a $192.00 target price (down previously from $208.00) on shares of GW Pharmaceuticals in a research report on Monday, February 5th. Bank of America lowered their price objective on GW Pharmaceuticals from $154.00 to $149.00 and set a buy rating on the stock in a research report on Tuesday, February 6th. Finally, Goldman Sachs upgraded GW Pharmaceuticals from a neutral rating to a buy rating and set a $174.00 price objective on the stock in a research report on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $146.38.
GW Pharmaceuticals stock traded up $4.00 during trading on Wednesday, hitting $122.51. The stock had a trading volume of 274,985 shares, compared to its average volume of 366,581. GW Pharmaceuticals has a 1 year low of $92.65 and a 1 year high of $143.37. The company has a current ratio of 11.44, a quick ratio of 11.34 and a debt-to-equity ratio of 0.01. The company has a market cap of $3,223.82, a price-to-earnings ratio of -17.63 and a beta of 2.62.
GW Pharmaceuticals (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. The firm had revenue of $7.73 million during the quarter, compared to analysts’ expectations of $2.18 million. equities research analysts forecast that GW Pharmaceuticals will post -9.66 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Eqis Capital Management Inc. increased its stake in GW Pharmaceuticals by 12.6% in the fourth quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 424 shares during the last quarter. Aperio Group LLC increased its stake in GW Pharmaceuticals by 12.0% in the fourth quarter. Aperio Group LLC now owns 5,325 shares of the biopharmaceutical company’s stock valued at $703,000 after acquiring an additional 569 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in GW Pharmaceuticals by 18.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 581 shares during the last quarter. Bank of Montreal Can increased its stake in GW Pharmaceuticals by 37.1% in the fourth quarter. Bank of Montreal Can now owns 2,625 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 710 shares during the last quarter. Finally, Raymond James & Associates increased its stake in GW Pharmaceuticals by 9.3% in the fourth quarter. Raymond James & Associates now owns 8,464 shares of the biopharmaceutical company’s stock valued at $1,117,000 after acquiring an additional 718 shares during the last quarter. 82.51% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Macon Daily and is the property of of Macon Daily. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://macondaily.com/2018/04/12/gw-pharmaceuticals-plc-gwph-lifted-to-hold-at-zacks-investment-research-updated-updated-updated.html.
GW Pharmaceuticals Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Get a free copy of the Zacks research report on GW Pharmaceuticals (GWPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.